Synedgen Inc. has completed IND-enabling studies for its lead candidate, MIIST-305, which is being developed for ulcerative colitis and as a medical countermeasure for gastrointestinal acute radiation syndrome. Within a year, Synedgen plans to file an IND application for MIIST-305 and initiate a phase I study to support both programs.
Acetaminophen overdose is still a major cause of liver toxicity (acute liver failure, ALI) in Western countries. It occurs by accumulation of the toxic metabolite NAPQI and the subsequent mitochondrial oxidative stress mediated by pJNK translocation to the mitochondria.
Purdue Research Foundation, The Brigham and Women's Hospital Inc., the University of California Oakland and University of Utah have developed platinum complexes for the treatment of cyanide poisoning.
Clearmind Medicine Inc. has received approval from Israel’s Ministry of Health to initiate a phase I/IIa trial of CMND-100 oral capsules for alcohol use disorder (AUD). The multinational trial in healthy volunteers and AUD subjects will be conducted in Israel and the U.S.
Burn injuries, including those induced by chemicals, may have systemic effects, and can lead to acute lung injury (ALI). Chemical burn injuries account for about 2% to 5% of total skin burn injuries. Among the chemicals, vesicating agents like Lewisite are particularly relevant due to the lack of antidotes.
Pharward Biotechnology Inc. Pte Ltd. has disclosed compounds acting as E3 ubiquitin-protein ligase SIAH1 modulators reported to be useful for the treatment of cocaine dependence.
Amygdala Neurosciences Inc. has described aldehyde dehydrogenase-2 (ALDH2) inhibitors reported to be useful for the treatment of anxiety disorder, binge eating disorder, alcoholism, and amphetamine, cocaine, nicotine and opioid dependence.
RTI International has identified squaramide derivatives acting as cannabinoid CB1 receptor allosteric modulators reported to be useful for the treatment of obesity and substance abuse and dependence.
Recent studies have identified 70 oxygenized phosphatidylcholine (PC)-containing epoxy and hydroperoxide groups that are generated in the early phase of acetaminophen (APAP)-induced acute liver injury. In a new study, researchers from the University of Tokyo focused on arachidonate PC and assessed the role of liver-specific LPCAT3 (lysophospholipid acyltransferase 3) on APAP-induced acute liver injury in mice.
Pluri Inc. has signed an agreement assigning the joint patent rights to develop its PLX cells for the treatment of cocaine addiction to BIRAD-Research & Development Company Ltd., the commercial arm of Bar-Ilan University.